Stability and biological activity evaluations of PEGylated human basic fibroblast growth factor.

about

Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing.

P2860

Q42121550-50F4BC96-BDC8-4D51-969B-2A55DE794A1F

P2860

Stability and biological activity evaluations of PEGylated human basic fibroblast growth factor.

Item

http://www.wikidata.org/entity/Q36196361

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Stability and biological activ ...... asic fibroblast growth factor.

@ast

Stability and biological activ ...... asic fibroblast growth factor.

@en

type

Item

label

Stability and biological activ ...... asic fibroblast growth factor.

@ast

Stability and biological activ ...... asic fibroblast growth factor.

@en

prefLabel

Stability and biological activ ...... asic fibroblast growth factor.

@ast

Stability and biological activ ...... asic fibroblast growth factor.

@en

P1476

Stability and biological activ ...... asic fibroblast growth factor.

@en

P2093

Dariush Norouzian Shamassebi

http://www.w3.org/2001/XMLSchema#string

Mina Sepahi

http://www.w3.org/2001/XMLSchema#string

Mohamad Ali Shokrgozar

http://www.w3.org/2001/XMLSchema#string

Saeid Bouzari

http://www.w3.org/2001/XMLSchema#string

Shahin Hadadian

http://www.w3.org/2001/XMLSchema#string

P2860

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation

Second-generation biopharmaceuticals.

Creating the next generation of protein therapeutics through rational drug design.

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1)

Basic fibroblast growth factor accelerates and improves second-degree burn wound healing.

Effect of pegylation on self-association of IFN-α2b.

Effect of pegylation on pharmaceuticals.

P304

176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2277-9175.164001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hasan Mirzahoseini

P577

2015-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26605215

http://www.w3.org/2001/XMLSchema#string

P932

4616999

http://www.w3.org/2001/XMLSchema#string

Stability and biological activity evaluations of PEGylated human basic fibroblast growth factor.

about

P2860

P2860

Stability and biological activity evaluations of PEGylated human basic fibroblast growth factor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932